Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
About this item
Full title
Author / Creator
Turner, Nicholas C. , Im, Seock-Ah , Saura, Cristina , Juric, Dejan , Loibl, Sibylle , Kalinsky, Kevin , Schmid, Peter , Loi, Sherene , Sunpaweravong, Patrapim , Musolino, Antonino , Li, Huiping , Zhang, Qingyuan , Nowecki, Zbigniew , Leung, Roland , Thanopoulou, Eirini , Shankar, Noopur , Lei, Guiyuan , Stout, Thomas J. , Hutchinson, Katherine E. , Schutzman, Jennifer L. , Song, Chunyan and Jhaveri, Komal L.
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In
PIK3CA
-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib–fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib–fulvestrant.
Alternative Titles
Full title
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
Authors, Artists and Contributors
Author / Creator
Im, Seock-Ah
Saura, Cristina
Juric, Dejan
Loibl, Sibylle
Kalinsky, Kevin
Schmid, Peter
Loi, Sherene
Sunpaweravong, Patrapim
Musolino, Antonino
Li, Huiping
Zhang, Qingyuan
Nowecki, Zbigniew
Leung, Roland
Thanopoulou, Eirini
Shankar, Noopur
Lei, Guiyuan
Stout, Thomas J.
Hutchinson, Katherine E.
Schutzman, Jennifer L.
Song, Chunyan
Jhaveri, Komal L.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_3122638664
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3122638664
Other Identifiers
ISSN
0028-4793,1533-4406
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2404625
